The News Central

NHS to Trial Blood Tests for Early Cancer Detection in 20,000 Patients

The trial across 200 GP surgeries will test three AI-assisted tests aimed at finding cancer sooner and cutting unnecessary referrals.

The NHS will trial blood tests designed to pick up cancer in its earliest stages in more than 20,000 patients at 200 GP surgeries. A GP orders the test, and the aim is to detect cancer earlier and reduce unnecessary hospital referrals for invasive tests. The first companies are Proteotype, with the Enlighten test, Pinpoint AI, with the PinPoint test, and Mercy Bioanalytics, with the Halo test, and more tests may be added later.

Enlighten measures patterns of circulating amino acid markers in blood plasma and uses AI to assess the possibility of breast, bowel, lung or prostate cancer. It is intended for people with vague symptoms or a known increased risk. No accuracy data or published results were given, and no start date was announced; the trial exists to test how well the tests work in real-world settings.